Omnicell price target lowered to $65 from $71 at Wells Fargo

Wells Fargo analyst Stan Berenshteyn lowered the firm’s price target on Omnicell to $65 from $71 and keeps an Overweight rating on the shares. The firm sees risks to consensus estimates ahead of Q4 results, but would use share weakness as a buying opportunity. Near-term revenue pressures mask an otherwise widening competitive moat and Omnicell’s growing role as a strategic health system partner, Wells Fargo says.